Rubicon Research ipo date, Share Price Target Tomorrow, 2025, 2026, 2030
Rubicon Research is a medicine-making company that makes both generic and speciality medicines for people in many countries. The company’s main office is in India, and it has research centres in India and Canada. It is known for making good-quality medicines, including drug-device products that help improve how medicines work. It has modern research labs that focus on new ideas to make medicines safer and more effective. The company’s factories in India follow global health and safety rules and are approved by the USFDA. Its products include tablets, liquids, sprays, eye drops, injections, creams, and combined medicines.
- 1 What is Rubicon Research Ltd IPO?
- 2 Rubicon Research IPO Details
- 3 Rubicon Research Share Price Target Tomorrow (Listing day price)
- 4 Rubicon Research Share Price Target 2025
- 5 Rubicon Research share price Target 2026
- 6 Share price Target 2027
- 7 Share price Target 2028
- 8 Share price Target 2029
- 9 Rubicon Research share price Target 2030
- 10 Share price Target 2040
- 11 Share Price Target 2050
- 12 Should I buy Rubicon Research stock?
- 13 Rubicon Research earnings results (Financials)
- 14 Is Rubicon Research stock good to buy? (bull case & bear case)
- 15 Rubicon Research IPO Promoter Holding
- 16 Objects of the Issue (Rubicon Research IPO Objectives)
- 17 Rubicon Research ipo gmp
- 18 Conclusion
- 19 FAQs
What is Rubicon Research Ltd IPO?
Rubicon Research was established in 1999 in Thane, Maharashtra, India, by Pratibha Pilgaonkar, Sudhir Pilgaonkar, and Maharukh Rustomjee. It is an Indian company that manufactures various types of medicines and healthcare products. They make tablets, capsules, liquids, eye drops, nasal sprays, injections, and creams. The company’s goal is to make safe, useful, and high-quality medicines for people in India and other countries, mainly the U.S. It has research centres in Thane (India) and Concord (Canada), and factories in Ambernath and Satara. It also has an office in New Jersey, U.S.A., to manage its business and product approvals.
Rubicon Research IPO Details
| IPO Date | October 9, 2025 to October 13, 2025 |
| Listing Date | 16 Oct 2025 |
| Face Value | ₹1 per share |
| Price Band | ₹461 to ₹485 per share |
| Minimum Investment | ₹13830 |
| Lot Size | 30 Shares |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 15,44,37,251 shares |
| Share Holding Post Issue | 16,47,46,529 shares |
The company manages its costs and business efficiently and has improved how it collects payments and uses its money, keeping cash flow healthy. After some earlier losses, profits and profit margins have become strong, and the company is earning good returns on its investments. Overall, it is in a healthy and stable position, with growing sales, good profits, and smooth operations, making it a strong pharmaceutical company.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
| Tomorrow | -30 | +121 |
It is an Indian medicine company that makes safe, high-quality, and new medicines that meet global standards, which helps it compete in these tough markets. It produces both common generic medicines and special medicines that help treat complex health problems. It follows all the rules carefully, keeps its medicines consistent and reliable, and earns trust from doctors, pharmacies, and patients worldwide. In 2025, its share price target would be ₹884, as per stock market analysts.
According to stock market analysts, its share price would be between ₹330 to ₹884 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 330 | 884 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| October | 400 | 644 |
| November | 330 | 725 |
| December | 570 | 884 |
The company focuses on research and development (R&D) with scientists. The Indian R&D centre in Thane is a large, well-equipped lab for general medicines, sterile products, and strong drugs. The Canadian centre in Ontario mainly works on medicines like nasal sprays and inhalers. These labs help the company to create better medicines, test them carefully, and find new ways to treat patients. In 2026, its share price target would be ₹1363, as per stock market analysts.
Its share price would be between ₹847 to ₹1363 in 2026, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 847 | 1363 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 847 | 964 |
| February | 851 | 1030 |
| March | 867 | 1065 |
| April | 884 | 1085 |
| May | 900 | 1112 |
| June | 924 | 1137 |
| July | 937 | 1152 |
| August | 951 | 1174 |
| September | 1054 | 1200 |
| October | 1078 | 1225 |
| November | 1125 | 1275 |
| December | 1174 | 1363 |
The company has created a special system for marketing, selling, and delivering medicines in the United States through its subsidiary, AdvaGen Pharma. This subsidiary takes care of non-branded prescription medicines and sends them to wholesalers, pharmacy chains, and big buying groups. It also keeps medicine stocks in different U.S. locations and works with experienced delivery partners to make sure medicines reach on time. In 2027, its share price target would be ₹1888, as per stock market analysts.
Its share price would be between ₹1320 to ₹1888 in 2027, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 1320 | 1888 |
The company has recovered earlier losses by managing costs, selling more, and working efficiently. Its focus on good-quality medicines, new technologies, and strict markets has made its financial performance stronger. This steady growth shows that it can expand my business while keeping things under control. Overall, it is a growing, stable, and strong pharmaceutical company with a solid base for future growth. In 2028, its share price target would be ₹2430, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1850 to ₹2430 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 1850 | 2430 |
The company focuses on making healthcare easier to access, improving education, protecting the environment, and helping local communities grow. By including these social and environmental concerns in its business work, it aims to make a positive difference and support long-lasting, sustainable development. Its efforts help people live better lives, protect nature, and show that the company is responsible and thoughtful toward both society and the planet. In 2029, its share price target would be ₹2962, as per stock market analysts.
According to stock market analysts, its share price would be between ₹2388 to ₹2962 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 2388 | 2962 |
It makes quality and safety its top priority. The company follows strict rules and standards to ensure its medicines are safe and effective for patients. Its facilities meet international approvals like the US FDA, MHRA UK, TGA Australia, and Vietnam’s Ministry of Health, showing the company’s strong focus on high standards. It aims to earn the trust of doctors, pharmacies, and patients worldwide and provide medicines that people can rely on. In 2030, its share price target would be ₹3487, as per stock market analysts.
Its share price would be between ₹2908 to ₹3487 in 2030, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 2908 | 3487 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2908 | 3037 |
| February | 2924 | 3075 |
| March | 2954 | 3094 |
| April | 2975 | 3124 |
| May | 2990 | 3157 |
| June | 3012 | 3190 |
| July | 3054 | 3221 |
| August | 3067 | 3257 |
| September | 3085 | 3290 |
| October | 3104 | 3354 |
| November | 3114 | 3390 |
| December | 3224 | 3487 |
The company teams up with other companies to grow and improve its medicines. The company can use new technologies, reach more markets, and get extra resources to help its business grow by working together. Partnerships also allow it to combine strengths and develop new products faster. These collaborations help the company become stronger and build a better position in the global pharmaceutical industry. In 2040, its share price target would be ₹5253, as per stock market analysts.
According to stock market analysts, its share price would be between ₹4670 to ₹5253 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 4670 | 5253 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 4670 | 4790 |
| February | 4690 | 4827 |
| March | 4700 | 4858 |
| April | 4732 | 4886 |
| May | 4752 | 4900 |
| June | 4778 | 4932 |
| July | 4823 | 4954 |
| August | 4852 | 4974 |
| September | 4867 | 5053 |
| October | 4887 | 5087 |
| November | 4935 | 5114 |
| December | 5014 | 5253 |
The company focuses on innovation, quality medicines, and following all rules, which helps it do well in strict healthcare markets. It has a wide range of products and is expanding in other countries, showing its commitment to improving patient care. With strong plans and operations, it has a solid foundation to reach its goals and keep growing steadily in the future. In 2050, its share price target would be ₹5881, as per stock market analysts.
Its share price would be between ₹5320 to ₹5881 in 2050, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 5320 | 5881 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 5320 | 5374 |
| February | 5352 | 5410 |
| March | 5374 | 5438 |
| April | 5390 | 5474 |
| May | 5421 | 5500 |
| June | 5437 | 5537 |
| July | 5456 | 5565 |
| August | 5478 | 5580 |
| September | 5500 | 5632 |
| October | 5521 | 5674 |
| November | 5547 | 5725 |
| December | 5584 | 5881 |
Should I buy Rubicon Research stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 330 | 884 |
| 2026 | 847 | 1363 |
| 2027 | 1320 | 1888 |
| 2028 | 1850 | 2430 |
| 2029 | 2388 | 2962 |
| 2030 | 2908 | 3487 |
| 2040 | 4670 | 5253 |
| 2050 | 5320 | 5881 |
The company focuses on strict markets, especially the U.S., which helps keep its medicines high-quality and in demand. Its strong research and development, special drug technologies, and wide range of products support long-term growth. But like other medicine companies, it faces competition and market risks. Overall, it is financially strong and ready to grow, but anyone thinking of investing should consider these risks and their own comfort with investing.
Rubicon Research earnings results (Financials)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
| Sales + | 263 | 315 | 314 | 394 | 854 | 1,284 |
| Expenses + | 182 | 223 | 353 | 375 | 699 | 1,028 |
| Operating Profit | 81 | 92 | -39 | 18 | 155 | 256 |
| OPM % | 31% | 29% | -12% | 5% | 18% | 20% |
| Other Income + | 18 | 10 | 17 | 25 | 18 | 12 |
| Interest | 6 | 9 | 10 | 19 | 31 | 37 |
| Depreciation | 18 | 29 | 34 | 36 | 39 | 37 |
| Profit before tax | 74 | 63 | -66 | -11 | 103 | 195 |
| Tax % | 33% | 51% | 2% | 53% | 12% | 31% |
| Net Profit + | 49 | 31 | -67 | -17 | 91 | 134 |
| EPS in Rs | ||||||
| Dividend Payout % | 2% | 2% | -0% | -2% | 0% | 0% |
Is Rubicon Research stock good to buy? (bull case & bear case)
Bull Case:
- Between FY2023 and FY2025, its revenue grew from ₹393.5 crore to ₹1,284.3 crore, a CAGR of 75.9%, showing very strong growth.
- The company’s net profit rose from a loss of ₹16.9 crore in FY2023 to a profit of ₹134.4 crore in FY2025, showing it turned around quickly.
- It focuses on regulated markets, especially the U.S., which are hard to enter and offer steady demand and good profits.
- The company has a Return on Capital Employed (ROCE) of 28.6% and Return on Equity (ROE) of 34.9%, meaning it uses its money efficiently.
- Its research and development team of 170 scientists in India and Canada helps the company create new products and get approvals fast.
- It has a portfolio of 69 active ANDAs and NDAs, with 55 commercialised products, showing it has many products ready to sell.
Bear Case:
- The pharmaceutical market is very competitive, and Rubicon faces strong competition from global and local companies.
- The company’s working capital days are 57, which is good, but any supply or inventory problems could affect cash flow.
- Debt has increased to ₹425 crore, which may make the company more vulnerable financially.
Rubicon Research IPO Promoter Holding
General Atlantic Singapore RR Pte. Ltd., Pratibha Pilgaonkar, Sudhir Dhirendra Pilgaonkar, Parag Suganchand Sancheti, Surabhi Parag Sancheti and Sumant Sudhir Pilgaonkar are the company promoters.
| Promoter Holding Pre Issue | 77.67% |
| Promoter Holding Post Issue | — |
Objects of the Issue (Rubicon Research IPO Objectives)
- It plans to use ₹3,100 million from the funds to prepay or repay part of its outstanding borrowings.
- The rest of the money will be used for funding growth through acquisitions, other strategic initiatives, and general corporate purposes.
Rubicon Research ipo gmp
| Date | IPO GMP | Gain |
| 7 Oct | ₹80 | 16.49% |
| 6 Oct | ₹68 | 14.02% |
Conclusion
The company makes both regular and special medicines for India and other countries, especially the U.S. It has strong research labs in India and Canada and modern factories approved by global health authorities. Its products include tablets, liquids, sprays, eye drops, injections, and creams. The company has recovered from past losses and now has growing sales, good profits, and smooth operations. It is strong and ready to grow, but investors should consider competition and risks with its focus on quality, innovation, and strict markets.
